Pharmaceuticals Hong Kong

Hong Kong Anti-Nerve Growth Factor Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

Hong Kong Anti-Nerve Growth Factor Market Analysis Industry Trends and Forecast to 2034: Segmented by (By Type, By Indication, By Agents, By Route of Administration, By End User, By Distribution channel, By Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Buy the full report

Report snapshot

Hong Kong Anti-Nerve Growth Factor Market Analysis at a glance
Market size, 2025Researched figures come with the full report
Forecast, 2034Researched figures come with the full report
Growth (CAGR), 2025–2034Researched figures come with the full report
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsType, indication, agents, route of administration, end user and distribution channel (see all)
Key playersPfizer Inc., Regeneron Pharmaceuticals, Teva Pharmaceutical, Sanofi, Mitsubishi Tanabe Pharma Corporation and 2 more (see all)
Regulator in Hong KongDrug OfficeSource: Drug Office, Department of Health. Checked 14 Nov 2026.
FormatsPDF, PPTX, XLSX

The Hong Kong Anti-Nerve Growth Factor Market Executive Summary

The utilization of anti-nerve growth factor (NGF) antibodies represents an innovative therapeutic approach in the realm of pain management, demonstrating efficacy in the treatment of specific pain disorders. NGF is classified as a neurotrophic factor that interacts with TrkA, a receptor that is prevalent in various sensory and sympathetic nerve fibers, thereby influencing the viability of these neuronal populations. A comprehensive epidemiological analysis conducted by Tsang et al. in 2008 reveals an age-standardized prevalence of chronic pain conditions over the preceding twelve months, recorded at 37.3% in developed nations and 41.1% in developing nations, culminating in an overall prevalence rate of 38.4%. Noteworthy examples of anti-NGF monoclonal antibodies (mAbs) encompass tanezumab, fulranumab, fasinumab, and ABT-110 (also known as PG110).

The market for anti-nerve growth factor (anti-NGF) therapies is an emerging domain within pain management, presenting innovative treatments such as tanezumab that specifically target the NGF signalling pathway to alleviate chronic pain disorders, including osteoarthritis. This market is propelled by an increasing demand for safer and more efficacious pain management solutions, bolstered by favourable clinical developments; however, it is also confronted with significant safety concerns, intricate regulatory challenges, and issues related to reimbursement. Nevertheless, there exist potential opportunities for the expansion of these therapeutic applications to additional pain conditions, international market growth, and the establishment of strategic partnerships. Effectively addressing these challenges will be imperative for the market to realize its complete potential.

Hong Kong Anti-Nerve Growth Factor Market Dynamics

Market Growth Drivers

There's a big gap in the market for pain medication that work well, since the ones we have now, like opioids and NSAIDs have drawbacks and cause side effects. Treatments that target NGF such as tanezumab, look promising in tests. They seem to help with pain and make it easier to move around for people with conditions like osteoarthritis. As more people live longer and deal with long-term pain, we need new ways to treat it. Drug companies are putting a lot of money into making anti-NGF drugs, which could help with many types of pain, both from injury and nerve damage. But there are some roadblocks to market growth worries about safety. Some serious problems have come up during testing. To make the anti-NGF market bigger, we'll need to tackle these safety issues head-on.

Opportunity

The anti-nerve growth factor (anti-NGF) market has bright prospects ahead. New treatments like tanezumab, fulranumab, and fasinumab could help with many types of pain. More uses for nociceptive and neuropathic pain might boost market demand. Mechanism-based pain therapies offer a safer alternative to traditional analgesics by targeting specific pain pathways. The market could grow a lot in up-and-coming areas like Asia-Pacific. Team-ups between drug companies, research groups, and health care providers will play a big role. To move the market forward, they'll need to focus on making treatments safer and work better.

Market Restraints

The market for anti-nerve growth factor (anti-NGF) is confronted with several critical constraints, including substantial safety apprehensions such as rapidly progressing osteoarthritis and osteonecrosis observed in clinical trials. Regulatory impediments and rigorous approval protocols can impede the timely introduction of innovative therapies. Unfavourable outcomes from certain late-stage clinical trials have hindered advancement, while competition from established analgesic alternatives such as opioids and non-steroidal anti-inflammatory drugs (NSAIDs) presents a formidable challenge. Insufficient patient awareness and issues surrounding reimbursement further exacerbate the complexities of market expansion. Effectively addressing these challenges is imperative for the growth and successful integration of anti-NGF therapies.

Competitive Landscape Anti-Nerve Growth Factor Market in Hong Kong

Key Players

Recent Developments

August 2024, Levicept's ex-Pfizer drug reduces osteoarthritis pain in phase 2.

October 2021, Lilly, Pfizer stop development of osteoarthritis drug after FDA rejection, extending bleak run for NGF inhibitors.

Merger and acquisition

October 2021, Pacira BioSciences to Acquire Flexion Therapeutics Further Expanding Leadership Position in Non-Opioid Pain Management

Healthcare Policies and Regulatory Landscape for Anti-Nerve Growth Factor Market in Hong Kong

Anti-Nerve Growth Factor in Hong Kong: rules and payment

Pharmaceutical products must be registered with the Pharmacy and Poisons Board before sale, through the Drug Office of the Department of Health.⁠[1] Public hospitals and clinics, run by the Hospital Authority, are heavily subsidised by the government.⁠[2]

[1] Drug Office, Department of Health. Checked 14 Nov 2026.

[2] Hospital Authority. Checked 14 Nov 2026.

Policy changes and Reimbursement scenario

Regulatory approvals and designations are of paramount importance in the advancement and market proliferation of anti-NGF therapeutics. For example, in 2017, the FDA conferred fast track designation upon tanezumab for the management of osteoarthritis and chronic low back pain, thereby accelerating its evaluative process. The optimization of regulatory approvals, while maintaining safety and efficacy standards, is critical for augmenting therapeutic alternatives. Nonetheless, obtaining sufficient reimbursement presents a substantial obstacle, as payers demand comprehensive evidence of sustained efficacy and economic viability in comparison to existing analgesic treatments. The establishment of policies that promote research and development while ensuring equitable pricing and reimbursement will be instrumental in improving patient access and facilitating market growth.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Anti-Nerve Growth Factor right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 9 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Anti-Nerve Growth Factor in context

Hong Kong compared

  • People aged 65 and over: 23.7% of people (2025). World: 10.4% of people (2025). 2nd highest of the 16 countries we cover in APAC.[1]

[1] World Bank Open Data, People aged 65 and over (% of people). Retrieved 16 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

What segments does the Anti-Nerve Growth Factor market report cover?
The report splits the market by type (Alpha-NGF, Beta-NGF, Gamma-NGF, Others), indication (Osteoarthritis, Chronic Pain, Neuropathic Pain, Other Indications), agents (Tanezumab, Fasinumab, Fulranumab, Other Agents) and route of administration (Parenteral, Oral).
Who are the key players in the Anti-Nerve Growth Factor market?
Key players include Pfizer Inc., Regeneron Pharmaceuticals, Teva Pharmaceutical, Sanofi, Mitsubishi Tanabe Pharma Corporation and Merck KGaA, among 7 companies the report profiles.
What is driving the Anti-Nerve Growth Factor market?
There's a big gap in the market for pain medication that work well, since the ones we have now, like opioids and NSAIDs have drawbacks and cause side effects. Treatments that target NGF such as tanezumab, look promising in tests.
Who regulates Anti-Nerve Growth Factor in Hong Kong?
Pharmaceutical products must be registered with the Pharmacy and Poisons Board before sale, through the Drug Office of the Department of Health. Source: Drug Office, Department of Health. Checked 14 Nov 2026.
How is healthcare paid for in Hong Kong?
Public hospitals and clinics, run by the Hospital Authority, are heavily subsidised by the government. Source: Hospital Authority. Checked 14 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in Hong Kong

See all

Related on pain and brain and nerves

See the topic